Genmab A/S Sponsored ADR (GMAB) vs Incyte Corporation (INCY)
- Genmab A/S Sponsored ADR GMAB 53.72 +1.86%
- Incyte Corporation INCY 119.31 +1.10%
Genmab A/S Sponsored ADR and Incyte Corporation are both Biotechnology companies. Genmab A/S Sponsored ADR is the larger, with a market value of $31.5B against $24.1B — 1.3× the size. Genmab A/S Sponsored ADR trades at the lower P/E: 41.7× against 56.3×. Incyte Corporation grew revenue faster over the last twelve months: 24.9% against 22.3%. Genmab A/S Sponsored ADR has the higher net margin (19.1% vs 6.71%) and the lower return on invested capital (6.99% vs 21.6%). Across the 21 metrics below, Incyte Corporation leads on 12 and Genmab A/S Sponsored ADR on 9.
Valuation
Profitability
| Metric | GMAB | INCY | Biotechnology median |
|---|---|---|---|
| Gross margin | 93.03% | 92.69% | 65.16% |
| Operating margin | 25.95% | 10.42% | 0.00% |
| Net margin | 19.08% | 6.71% | 0.00% |
| Free cash flow margin | (153.64%) | 11.31% | 0.00% |
| Return on equity | 14.00% | 7.84% | (50.12%) |
| Return on assets | 8.30% | 5.92% | (45.60%) |
| Return on invested capital | 6.99% | 21.56% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack